Mycobacterium chimaera Pulmonary Disease in Cystic Fibrosis Patients, France, 2010-2017

Emerging Infectious Diseases
Romaric LarcherSylvain Godreuil

Abstract

We report Mycobacterium chimaera pulmonary disease in 4 patients given a diagnosis of cystic fibrosis in a university hospital in Montpellier, France. All patients had M. chimaera-positive expectorated sputum specimens, clinical symptoms of pulmonary exacerbation, or a decrease in spirometry test results that improved after specific treatment.

References

Jul 29, 2004·International Journal of Systematic and Evolutionary Microbiology·Enrico TortoliClaudio Scarparo
Oct 27, 2006·FEMS Immunology and Medical Microbiology·Enrico Tortoli
Feb 6, 2007·American Journal of Respiratory and Critical Care Medicine·David E GriffithUNKNOWN Infectious Disease Society of America
Feb 17, 2009·Diagnostic Microbiology and Infectious Disease·Nathan D BillsPeter C Iwen
Sep 24, 2011·Journal of Medical Case Reports·Stéphan Cohen-BacrieMichel Drancourt
Apr 4, 2015·American Journal of Respiratory and Critical Care Medicine·Daniel P BoyleChao Qi
May 4, 2016·Lancet·J Stuart Elborn
Nov 5, 2016·Diagnostic Microbiology and Infectious Disease·Seong Mi MoonWon-Jung Koh

❮ Previous
Next ❯

Citations

Mar 24, 2020·Expert Opinion on Pharmacotherapy·Maria-Carmen Muñoz-EgeaJaime Esteban
Oct 11, 2020·International Journal of Environmental Research and Public Health·Matteo BolcatoAnna Aprile

❮ Previous
Next ❯

Methods Mentioned

BETA
fluorescence microscopy

Related Concepts

Related Feeds

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.